Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group
IMUNON Announces Withdrawal of Form S-1 Registration Statement
05:20pm, Thursday, 22'nd May 2025
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has fil
Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines
Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript
12:56pm, Monday, 12'th May 2025
Imunon, Inc. (NASDAQ:IMNN ) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, Investor Relations Stacy Lindborg - President & Chief Executive
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
08:00am, Monday, 12'th May 2025
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at
IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
08:05am, Thursday, 08'th May 2025
Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit
Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a cli
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
08:00am, Monday, 05'th May 2025
LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company w
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
08:05am, Monday, 21'st Apr 2025
Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
08:00am, Monday, 24'th Mar 2025
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer
Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript
02:32pm, Thursday, 27'th Feb 2025
Imunon, Inc. (NASDAQ:IMNN ) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, IR Stacy Lindborg - President & Chief Executive Officer Dou
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
08:05am, Wednesday, 26'th Feb 2025
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
08:30am, Thursday, 20'th Feb 2025
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
08:05am, Wednesday, 19'th Feb 2025
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose
